|
Video: What is a Stock Split?
|
|
Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. Co.'s clinical-stage pipeline include: AVTX-002, which is a fully human monoclonal antibody, directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator, a receptor expressed by T lymphocytes) being developed for the treatment of non-eosinophilic asthma; AVTX-008, which is a fully human B and T Lymphocyte Attenuator agonist fusion protein; and AVTX-803, which is a fucose replacement for leukocyte adhesion deficiency type II. According to our AVTX split history records, Avalo Therapeutics has had 2 splits. | |
|
Avalo Therapeutics (AVTX) has 2 splits in our AVTX split history database. The first split for AVTX took place on July 08, 2022. This was a 1 for 12 reverse split, meaning for each 12 shares of AVTX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 83.3333333333333 share position following the split. AVTX's second split took place on December 29, 2023. This was a 1 for 240 reverse split, meaning for each 240 shares of AVTX owned pre-split, the shareholder now owned 1 share. For example, a 83.3333333333333 share position pre-split, became a 0.347222222222222 share position following the split.
When a company such as Avalo Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the AVTX split history from start to finish, an original position size of 1000 shares would have turned into 0.347222222222222 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Avalo Therapeutics shares, starting with a $10,000 purchase of AVTX, presented on a split-history-adjusted basis factoring in the complete AVTX split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/15/2015 |
|
End date: |
04/25/2024 |
|
Start price/share: |
$18,432.00 |
|
End price/share: |
$14.98 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.92% |
|
Average Annual Total Return: |
-56.56% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$8.12 |
|
Years: |
8.53 |
|
|
|
Date |
Ratio |
07/08/2022 | 1 for 12 | 12/29/2023 | 1 for 240 |
|
|